- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Allergan, FDA communicate on Botox ads
Irvine, Calif. - Allergan Inc., contrary to popular belief, isn't fighting the U.S. Food and Drug Administration's allegations that statements in Botox Cosmetic advertisements are misleading, thus violating of the Food, Drug, and Cosmetic Act.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
What Dermatologists Need to Know About the Future of Regenerative Aesthetics
Redefining Anti-Aging with Regenerative Aesthetics and Growth Factor Skincare
Bridging the Communication Gap Between Providers and Patients Through the Skin Quality Index
Allergan Aesthetics' Effort to Create a Unified Vocabulary for Skin Quality
Tattoo Ink Risks, MultiFrax Laser, and the Impact of GLP-1 Medications on Skin Health
How Mindy Haws, MD, Empowers Women in Aesthetic Medicine
LIMITLESS: A Collaborative Effort Between Allergan, The Aesthetic Society, and The American Society of Plastic Surgeons
How the LIMITLESS Initiative Supports Female Leaders in Dermatology
Aesthetic Treatments: More Than Just Enhancements, A Path to Empowerment
Four Key Factors When Buying Dermatology Devices
Related Content
